Tags are keywords. I put tags on every post to help you find the content you want. Tags may be people (Dominic Raab, say), organisations (The Howard League, PRT), themes (women offenders, homelessness) or specific items (heroin, racial disparity, ROTL). If you’re looking to research a particular issue, they can be invaluable.
Traditional substance use prevention has focused on warning or informing about risks or on skills-based interventions. Why not aim to limit unhealthy behaviours by changing the environment in ways which influence people’s choices?
EMCDDA/EUROPOL report identifies growing use of darknet for drug dealing and calls for international co-operation to prevent continued growth.
Europe’s leading drug policy organisation issues a new comprehensive guide highlights the swiftly changing nature of both drug problems & effective responses.
The 2017 EMCDDA European Drug Report highlights concerns over drug overdoses, new drugs, the rise of fentanyl and whether EU countries will legalise cannabis.
European Drug Report puts the UK in a European context, highlights our high levels of heroin, cocaine & MDMA use and our troubling drug-induced mortality rate.
The latest United Kingdom Drug Situation report reveals an increase in the purity of heroin and cocaine and that only 5% of cannabis is now resin.
New online resource from European Centre for Monitoring Drugs and Drug Abuse provides excellent concise overview of €24billion European drug markets.
New wastewater analysis from SCORE and EMCDDA reveals that Londoner use more cocaine per head in the week than any other major European city.
New publications from EMCDDA and Public Health England show high rates of hepatitis c (frequently undiagnosed) among injecting drug users.
New systematic review from the EMCDDA suggests that “contingency management” (financially rewarding drug users) is effective at helping them stay in treatment.
New EMCDDA publication reports on the resurgence of Ecstasy/MDMA use with much stronger pills presenting a particular risk.
Europe, both as individual countries and, collectively, as the EU may have good intelligence about the way the European drug markets work but has limited impact on disrupting them.
